# SWOG S1702 (NCT03499808)

> S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

No report yet. It can be ordered.

- Drugs tested: isatuximab
- Indication: relapsed and/or refractory AL amyloidosis

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03499808
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
- Interventions: Isatuximab; Laboratory Biomarker Analysis
- Enrollment: 43
- Primary outcome: Assess Efficacy by Confirmed Overall Hematologic Response

## Indexed commentary on SWOG S1702 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=swog-s1702-nct03499808

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03499808", "email": "<work email>"}; the inbox owner confirms by the emailed link.